Literature DB >> 12019074

High prevalence of high-level ciprofloxacin resistance in Neisseria gonorrhoeae in Tel Aviv, Israel: correlation with response to therapy.

Michael Dan1, Francesca Poch, Bracha Sheinberg.   

Abstract

A survey of the drug susceptibilities of gonococcal isolates from 100 consecutive patients attending clinics in the Tel Aviv area of Israel during the period from February to September 2000 has shown a 61% rate of ciprofloxacin resistance (MICs, > or =1 microg/ml); 51 isolates were highly resistant (MICs, > or =4 microg/ml). Ciprofloxacin-resistant strains were more prevalent among isolates with chromosomally mediated resistance to penicillin and tetracycline. Therapeutic failures with ciprofloxacin correlated with MICs of > or =1 mg/ml (P < 0.01). The high rate of ciprofloxacin resistance coinciding with a sharp rise in the incidence of gonorrhea precludes the use of fluoroquinolone drugs for the empirical treatment of gonococcal infections acquired in Israel.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12019074      PMCID: PMC127211          DOI: 10.1128/AAC.46.6.1671-1673.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  High-level quinolone resistance in Neisseria gonorrhoeae: a report of two cases.

Authors:  J W Tapsall; E A Limnios; C Thacker; B Donovan; S D Lynch; L J Kirby; K A Wise; C J Carmody
Journal:  Sex Transm Dis       Date:  1995 Sep-Oct       Impact factor: 2.830

2.  Antimicrobial resistance in Neisseria gonorrhoeae in the United States, 1988-1994: the emergence of decreased susceptibility to the fluoroquinolones.

Authors:  K K Fox; J S Knapp; K K Holmes; E W Hook; F N Judson; S E Thompson; J A Washington; W L Whittington
Journal:  J Infect Dis       Date:  1997-06       Impact factor: 5.226

3.  Comparative double-blind study of 200- and 400-mg enoxacin given orally in the treatment of acute uncomplicated urethral gonorrhea in males.

Authors:  A H van der Willigen; J C van der Hoek; J H Wagenvoort; H J van Vliet; B van Klingeren; W O Schalla; J S Knapp; T van Joost; M F Michel; E Stolz
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

4.  Analysis of the antibiotic sensitivity of Neisseria gonorrhoeae in Guangzhou, Peoples Republic of China.

Authors:  C Wenling; Z Xibao; F Shi; W Minchang; L Ping; W Debiao; Y Jinlan
Journal:  Sex Transm Dis       Date:  2000-09       Impact factor: 2.830

5.  Intercity spread of gonococci with decreased susceptibility to fluoroquinolones: a unique focus in the United States.

Authors:  P H Kilmarx; J S Knapp; M Xia; M E St Louis; S W Neal; D Sayers; L J Doyle; M C Roberts; W L Whittington
Journal:  J Infect Dis       Date:  1998-03       Impact factor: 5.226

6.  Antimicrobial susceptibilities and plasmid contents of Neisseria gonorrhoeae isolates from commercial sex workers in Dhaka, Bangladesh: emergence of high-level resistance to ciprofloxacin.

Authors:  B U Bhuiyan; M Rahman; M R Miah; S Nahar; N Islam; M Ahmed; K M Rahman; M J Albert
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

7.  Comparative assessment of Etest for testing susceptibilities of Neisseria gonorrhoeae to penicillin, tetracycline, ceftriaxone, cefotaxime, and ciprofloxacin: investigation using 510(k) review criteria, recommended by the Food and Drug Administration.

Authors:  D J Biedenbach; R N Jones
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

8.  Fluoroquinolone-resistant Neisseria gonorrhoeae--San Diego, California, 1997.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1998-05-29       Impact factor: 17.586

9.  High-level ciprofloxacin resistance in Neisseria gonorrhoeae: first report from Israel.

Authors:  M Dan; F Poch; D Shpitz; B Sheinberg
Journal:  Emerg Infect Dis       Date:  2001 Jan-Feb       Impact factor: 6.883

10.  Antimicrobial susceptibilities of Neisseria gonorrhoeae strains representing five distinct resistance phenotypes.

Authors:  R J Rice; J S Knapp
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

View more
  8 in total

1.  Use of applied biosystems 7900HT sequence detection system and Taqman assay for detection of quinolone-resistant Neisseria gonorrhoeae.

Authors:  Julie Giles; Justin Hardick; Jeffrey Yuenger; Michael Dan; Karl Reich; Jonathan Zenilman
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

2.  Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.

Authors:  Vanessa G Allen; David J Farrell; Anuradha Rebbapragada; Jingyuan Tan; Nathalie Tijet; Stephen J Perusini; Lynn Towns; Stephen Lo; Donald E Low; Roberto G Melano
Journal:  Antimicrob Agents Chemother       Date:  2010-11-22       Impact factor: 5.191

3.  Real-time PCR assay for detection of quinolone-resistant Neisseria gonorrhoeae in urine samples.

Authors:  Mark J Siedner; Mark Pandori; Lina Castro; Pennan Barry; William L H Whittington; Sally Liska; Jeffrey D Klausner
Journal:  J Clin Microbiol       Date:  2007-01-31       Impact factor: 5.948

Review 4.  Gonorrhoea.

Authors:  Sarah Creighton
Journal:  BMJ Clin Evid       Date:  2011-03-14

Review 5.  Gonorrhoea.

Authors:  Sarah Creighton
Journal:  BMJ Clin Evid       Date:  2014-02-21

Review 6.  Gonorrhoea.

Authors:  John S Moran
Journal:  BMJ Clin Evid       Date:  2007-03-01

7.  Distinguishing importation from diversification of quinolone-resistant Neisseria gonorrhoeae by molecular evolutionary analysis.

Authors:  Marcos Pérez-Losada; Keith A Crandall; Margaret C Bash; Michael Dan; Jonathan Zenilman; Raphael P Viscidi
Journal:  BMC Evol Biol       Date:  2007-06-01       Impact factor: 3.260

8.  Drug-resistant Neisseria gonorrhoeae in Michigan.

Authors:  Kathryn E Macomber; Martha S Boehme; James T Rudrik; Dara Ganoczy; Erin Crandell-Alden; William A Schneider; Patricia A Somsel
Journal:  Emerg Infect Dis       Date:  2005-07       Impact factor: 6.883

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.